Recent News

• 08.06.2025 - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.06.2025 - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 08.06.2025 - Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update
• 06.25.2025 - Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
• 06.25.2025 - Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
• 06.25.2025 - Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
• 05.14.2025 - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.14.2025 - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update
• 05.14.2025 - Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

Recent Filings

• 08.06.2025 - EX-99.1 EX-99.1
• 08.06.2025 - 4 Statement of changes in beneficial ownership of securities
• 08.06.2025 - 8-K Current report
• 08.06.2025 - 3 Initial statement of beneficial ownership of securities
• 08.06.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 06.25.2025 - EX-99.1 EX-99.1
• 06.25.2025 - 8-K Current report
• 05.23.2025 - 8-K Current report
• 05.14.2025 - 8-K Current report
• 05.14.2025 - EX-99.1 EX-99.1